MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

Search

Crinetics Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

28.38 -1.22

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.24

Максимум

29.19

Ключови измерители

By Trading Economics

Приходи

-16M

-97M

Продажби

361K

361K

EPS

-1.04

Марж на печалбата

-26,807.202

Служители

437

EBITDA

-17M

-110M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+162.27% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-467M

2.7B

Предишно отваряне

29.6

Предишно затваряне

28.38

Настроения в новините

By Acuity

50%

50%

163 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.07.2025 г., 23:09 ч. UTC

Печалби

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1.07.2025 г., 19:16 ч. UTC

Придобивния, сливания и поглъщания

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1.07.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1.07.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1.07.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

James Hardie: Deal Represents Implied Value of $8.4 Billion

1.07.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1.07.2025 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

James Hardie Completes Acquisition of AZEK

1.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.07.2025 г., 20:24 ч. UTC

Печалби

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1.07.2025 г., 19:55 ч. UTC

Пазарно говорене

Oil Futures Resume Cautious Rally -- Market Talk

1.07.2025 г., 19:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1.07.2025 г., 19:12 ч. UTC

Пазарно говорене

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1.07.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1.07.2025 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1.07.2025 г., 18:33 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

1.07.2025 г., 18:33 ч. UTC

Пазарно говорене

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1.07.2025 г., 18:32 ч. UTC

Пазарно говорене

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1.07.2025 г., 18:22 ч. UTC

Пазарно говорене

Remittances to Mexico Down in May -- Market Talk

1.07.2025 г., 17:45 ч. UTC

Пазарно говорене

Seasonal Demand Supports Further Oil Gains -- Market Talk

1.07.2025 г., 17:01 ч. UTC

Придобивния, сливания и поглъщания

Danone Completed Acquisition of Majority Stake in Kate Farms

1.07.2025 г., 16:55 ч. UTC

Печалби

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1.07.2025 г., 16:27 ч. UTC

Пазарно говорене

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1.07.2025 г., 16:25 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.07.2025 г., 15:48 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1.07.2025 г., 15:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

1.07.2025 г., 15:46 ч. UTC

Пазарно говорене

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1.07.2025 г., 14:54 ч. UTC

Пазарно говорене

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1.07.2025 г., 14:49 ч. UTC

Пазарно говорене

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Crinetics Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

162.27% нагоре

12-месечна прогноза

Среден 75.43 USD  162.27%

Висок 97 USD

Нисък 60 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Crinetics Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

8

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

30.39 / 33.46Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

163 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.